T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CERE
426
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $166M | 0.02% |
5,224,800
+425,093
| +9% | +$13M |
|
|
PPLI
427
People Inc
PPLI
$3.02B
| $164M | 0.02% |
3,192,612
-17,543
| -0.5% | -$804K |
|
|
BNY
428
Bank of New York Mellon
BNY
$111B
| $163M | 0.02% |
3,666,448
+2,235,409
| +156% | +$95.9M |
|
429
Fair Isaac
FICO
$22.6B
| $163M | 0.02% |
201,707
+31,191
| +18% | +$23.4M |
|
430
Ventas
VTR
$45.7B
| $163M | 0.02% |
3,445,840
-47,086
| -1% | -$2.13M |
|
431
Bunge Global
BG
$21.5B
| $162M | 0.02% |
1,720,074
-171,750
| -9% | -$15.9M |
|
432
Peloton Interactive
PTON
$2.38B
| $161M | 0.02% |
20,910,838
-19,538,863
| -48% | -$166M |
|
433
Scholastic
SCHL
$792M
| $158M | 0.02% |
4,075,166
-189,854
| -4% | -$7.37M |
|
434
Dover
DOV
$28B
| $158M | 0.02% |
1,073,355
-1,103,709
| -51% | -$158M |
|
435
Ionis Pharmaceuticals
IONS
$9.39B
| $157M | 0.02% |
3,835,867
-99,084
| -3% | -$3.81M |
|
436
Mettler-Toledo International
MTD
$28.8B
| $155M | 0.02% |
118,011
-183,203
| -61% | -$258M |
|
|
AKRO
437
DELISTED
Akero Therapeutics
AKRO
| $154M | 0.02% |
3,289,643
+665,963
| +25% | +$30.5M |
|
438
Super Micro Computer
SMCI
$24.3B
| $153M | 0.02% |
6,158,250
+5,928,480
| +2,580% | +$99.3M |
|
|
AIV
439
Aimco
AIV
$379M
| $153M | 0.02% |
17,946,816
-6,125
| -0% | -$49.8K |
|
|
CMA
440
PUT
DELISTED
Comerica
CMA
| $152M | 0.02% |
+3,599,300
| New | +$145M |
|
441
Bruker
BRKR
$9.03B
| $151M | 0.02% |
2,046,315
-637,454
| -24% | -$48.6M |
|
442
Guardant Health
GH
$22.2B
| $151M | 0.02% |
4,215,380
+2,532,687
| +151% | +$72.7M |
|
443
Zscaler
ZS
$28.7B
| $150M | 0.02% |
1,022,577
+537,081
| +111% | +$65.6M |
|
444
International Flavors & Fragrances
IFF
$21.4B
| $149M | 0.02% |
1,874,904
-2,701,124
| -59% | -$232M |
|
445
10x Genomics
TXG
$7.52B
| $148M | 0.02% |
2,657,324
+243,364
| +10% | +$13.2M |
|
446
NOV
NOV
$7.45B
| $148M | 0.02% |
9,225,202
-741,596
| -7% | -$12.1M |
|
447
Raymond James Financial
RJF
$34.9B
| $148M | 0.02% |
1,421,484
+82,139
| +6% | +$7.63M |
|
448
Atmos Energy
ATO
$28.7B
| $147M | 0.02% |
1,266,139
-112,947
| -8% | -$13.1M |
|
449
Aptiv
APTV
$10.1B
| $147M | 0.02% |
1,439,022
-1,284,962
| -47% | -$127M |
|
450
Moderna
MRNA
$25.4B
| $146M | 0.02% |
1,201,434
-411,017
| -25% | -$54.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.